Valuation : Viking Therapeutics, Inc.

Market Cap 3.93B 3.39B 3.19B 2.9B 5.46B 373B 5.49B 37.68B 14.66B 190B 14.75B 14.43B 629B P/E 2026 *
-7.3x
P/E 2027 * -7.93x
Enterprise Value 3.49B 3.01B 2.83B 2.58B 4.85B 331B 4.88B 33.46B 13.02B 168B 13.1B 12.81B 558B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.91%
Yield 2026 *
-
Yield 2027 * -
1 day+0.04%
1 week+0.44%
Current month+5.34%
1 month+5.89%
3 months+17.89%
6 months+3.57%
Current year-1.85%
1 week 31.7
Extreme 31.7
34.75
1 month 31.28
Extreme 31.28
36.26
Current year 25.77
Extreme 25.77
42.79
1 year 22.96
Extreme 22.959
43.15
3 years 8.28
Extreme 8.28
99.41
5 years 2.02
Extreme 2.02
99.41
10 years 0.88
Extreme 0.88
99.41
Manager TitleAgeSince
Chief Executive Officer 60 2012-09-23
Director of Finance/CFO 55 2021-01-03
Chief Tech/Sci/R&D Officer 57 2026-06-10
Director TitleAgeSince
Chairman 68 2015-04-30
Chairman 60 2012-09-23
Director/Board Member 53 2014-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/1/26 Free

Director

47,133 0.0404%
7/29/26 Sell

Chief Operating Officer

-18,217 0.0157%
7/29/26 Sell

Founder

-148,517 0.1279%
Change 5-day change 1-year change 3-year change Capi.($)
+0.09%+0.44%+25.61%+143.86% 3.93B
-0.25%-4.10%+38.38%+92.61% 68.21B
+2.69%+1.45%+50.26%+91.75% 64.25B
+1.31%+0.23%-14.19%+372.81% 26.54B
+2.47%-7.35%+3.65%-14.52% 25.61B
+1.58%+1.62%+32.81%-17.61% 19.88B
-6.09%-12.08%+226.11%+375.00% 17.13B
+0.65%-5.28%-1.12%+534.90% 14.93B
+1.42%+4.55%+57.75%+163.36% 14.1B
+1.00%+1.92%+26.02%+197.87% 12.45B
Average +0.52%-3.68%+44.53%+194.00% 26.7B
Weighted average by Cap. +0.88%-3.20%+42.36%+154.01%

Financials

2026 *2027 *
Net sales - -
Net income -541M -467M -439M -400M -752M -51.37B -756M -5.19B -2.02B -26.13B -2.03B -1.99B -86.64B -539M -465M -438M -399M -750M -51.18B -754M -5.17B -2.01B -26.03B -2.02B -1.98B -86.33B
Net Debt -439M -379M -356M -325M -611M -41.69B -614M -4.21B -1.64B -21.21B -1.65B -1.61B -70.32B -520M -448M -422M -384M -722M -49.33B -726M -4.99B -1.94B -25.09B -1.95B -1.91B -83.2B
Logo Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
Employees
65
Date Price Change Volume
26-09-02 US$34.43 +2.26% 203,997
26-09-01 US$33.67 +2.72% 1,679,415
26-08-31 US$32.78 +1.93% 1,782,497
26-08-28 US$32.16 -5.02% 2,379,840
26-08-27 US$33.86 -1.51% 2,207,014
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
33.67USD
Average target price
92.39USD
Spread / Average Target
+174.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VKTX Stock